Journals / Klimik Dergisi / 2011 / Cilt: 24 - Sayı: 1

Tularemia: A general overview on current treatment options

Tularemi: Güncel tedavi seçeneklerine genel bir bakış

Pages
2–10
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, suggestions about treatment of tularemia are presented in the light of current literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Tularemia is a zoonotic infection caused by Francisella tularensis with a worldwide distribution and diverse clinical manifestations.
📊
Key Findings & Data:In humans, the disease varies from a localized illness to fulminant, life-threatening pneumonia or septicemia.
💡
Conclusion & Impact:In this review, suggestions about treatment of tularemia are presented in the light of current literature.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Tularemia is a zoonotic infection caused by Francisella tularensis with a worldwide distribution and diverse clinical manifestations. In humans, the disease varies from a localized illness to fulminant, life-threatening pneumonia or septicemia. For decades, streptomycin, gentamicin, and tetracycline have been used for the treatment of tularemia, but more recently, quinolones have been considered as acceptable alternatives. However, there are no randomized trials supporting the use of these antibiotics compared with each other. The increasing number of tularemia outbreaks in regions of Turkey outside the classic endemic areas in recent years has prompted renewed interest in this infectious disease. In this review, suggestions about treatment of tularemia are presented in the light of current literature.

Özet

Tularemi, Francisella tularensisin etken olduğu, dünya çapında bir dağılım gösteren ve farklı klinik belirtilerle seyreden zoonotik bir infeksiyon hastalığıdır. İnsanlarda klinik tablo lokalize hastalıktan fülminan, yaşamı tehdit eden pnömoni veya septisemiye kadar değişmektedir. Tularemi tedavisinde yıllardır streptomisin, gentamisin ve tetrasiklin kullanılmaktadır, ancak son zamanlarda kinolonlar önemli bir alternatif olarak kabul edilmektedir. Buna rağmen tularemi tedavisinde antibiyotiklerin etkinliklerini karşılaştıran randomize kontrollü çalışmalar bulunmamaktadır. Son yıllarda ülkemizde tulareminin endemik olduğu bölgeler dışında görülen salgınlarındaki artış bu hastalığa karşı ilgiyi artırmıştır. Bu derlemede, tularemi tedavisi hakkındaki öneriler güncel literatür ışığında sunulmuştur.

🔖

Cite This Article

KILIÇ, S., YEŞİLYURT, M. (2022). Tularemia: A general overview on current treatment options. Klimik Dergisi, Cilt: 24 - Sayı: 1, 2–10. https://ajindex.com/articles/652930

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Ellis J, Oyston PC, Green M, Titball RW. Tularemia. Clin Microbiol Rev. 2002
  2. 15(4): 631-46. [Crossref] 2.WHO Guidelines on Tularaemia [İnternet]. Geneva: World Health Organization [erişim 2 Mart 2011]. http://www.who.int/csr/resources/publications/WHO_CDS_EPR_2007_7.pdf. 3.Sjöstedt A. Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. Ann N Y Acad Sci. 2007
  3. Penn RL. Francisella tularensis (tularemia). In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 6th ed. Philadelphia: Churchill Livingstone, 2005: 2674-85. 5.Kılıç S. Francisella tularensis ve Türkiye’de tularemi epidemiyolojisine genel bir bakış. Flora. 2010
  4. 15(2): 37-58. 6.Tärnvik A, Berglund L. Tularemia. Eur Respir J. 2003
  5. 21(2): 361-73. [Crossref] 7.Tärnvik A, Chu MC. New approaches to diagnosis and therapy of tularemia. Ann N Y Acad Sci. 2007
  6. Hepburn MJ, Simpson AJ. Tularemia: current diagnosis and treatment options. Expert Rev Anti Infect Ther. 2008
  7. 6(2): 231-40. [Crossref] 9.Ericsson M, Sandström G, Sjöstedt A, Tärnvik A. Persistence of cell-mediated immunity and decline of humoral immunity to th intracellular bacterium Francisella tularensis 25 years after natural infection. J Infect Dis. 1994
  8. 170(1): 110-4. [Crossref] 10.Evans ME, Gregory DW, Schaffner W, McGee ZA. Tularemia: a 30- year experience with 88 cases. Medicine (Baltimore). 1985
  9. 64(4): 251-69. [Crossref] 11.Centers for Diseases Control (CDC). Tularemic pneumonia – Tennessee. MMWR Morb Mortal Wkly Rep. 1983
  10. 32(20): 262-4. 12.Provenza JM, Klotz SA, Penn RL. Isolation of Francisella tularensis from blood. J Clin Microbiol. 1986
  11. 24(3): 453-5. 13.Hofinger DM, Cardona L, Mertz GJ, Davis LE. Tularemic meningitis in the United States. Arch Neurol. 2009
  12. 66(4): 523-7. [Crossref] 14.Penn RL, Kinasewitz GT. Factors associated with a poor outcome in tularemia. Arch Intern Med. 1987
  13. 147(2): 265-8. [Crossref] 15.Christenson B. An outbreak of tularemia in the northern part of central Sweden. Scand J Infect Dis. 1984
  14. 16(3): 285-90. [Crossref] 16.Pérez-Castrillón JL, Bachiller-Luque P, Martín-Luquero M, Mena- Martín FJ, Herreros V. Tularemia epidemic in northwestern Spain: clinical description and therapeutic response. Clin Infect Dis. 2001
  15. 33(4): 573-6. [Crossref] 17.Enderlin G, Morales L, Jacobs RF, Cross JT. Streptomycin and alternative agents for the treatment of tularemia: review of the literature.